FDA approves neladalkib for ALK-positive lung cancer
MDSpire News
November 18, 2026
You now have access to the trusted editorial news and specialty content you've known from the Conexiant news site—all within the MDSpire experience.
Learn more

The FDA granted accelerated approval to neladalkib for adults with locally advanced or metastatic ALK-positive NSCLC after specified prior targeted therapy.
Eligible patients had received alectinib as their only prior ALK TKI in the advanced setting or at least 2 ALK TKIs and platinum-based chemotherapy.
In ALKOVE-1, the confirmed overall response rate was 49% among 67 patients previously treated only with alectinib and 32% among 155 patients in the other treatment group.
Among responders, 76% and 52% in the alectinib-only group maintained responses for at least 6 and 12 months, respectively; corresponding rates in the other group were 69% and 51%.
Neladalkib is taken orally at 150 mg once daily; warnings include hepatotoxicity, renal and ocular toxicity, elevated creatine phosphokinase, and embryo-fetal toxicity.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
Affiliations:
Specialties:
Areas of Expertise: